DOST undertakes PH formulation of Ivermectin

 

After a long wait on the study of the most talked-about drug, it’s finally here.
The Department of Science and Technology (DoST) has announced that it will manufacture its own dose of the anti-parasitic drug known as Ivermectin to support studies that would determine its efficacy, safety, and effect among asymptomatic and non-severe Covid-19 patients.

 

MANILA — In a radio interview, science and technology undersecretary Rowena Guevarra revealed that the project’s goal is to develop its own formulation of Ivermectin, which some claim is a Covid-19 treatment drug.

“Our team has decided that the Ivermectin formula will be done at the University of the Philippines Manila College of Pharmacy (UP-MCP). We will no longer buy regular formula because we will have our own dosage,” Guevarra explained.

She noted that the delay in the international clinical trial on Ivermectin prompted the agency to make the decision even as the country has been listed as among the participants of the international clinical trial on Ivermectin which was postponed due to revisions in the study protocols.

“For the Ivermectin consortia, they made changes so they need to get approval from the Food and Drug Administration,” Guevarra said.

To date, the Philippines has started its eight-month-long clinical trial of the Ivermectin drug at the UP Diliman, Ateneo de Manila University AdMU), De La Salle University (DLSU) and Makati Science High School (MSHS) quarantine facilities.

Guevarra stated that they will be recruiting (patients) from Regions 2 and 11, with the study scheduled to be completed this month and preliminary results expected by the end of the year.

Earlier, the Philippine Council for Health Research and Development (DOST-PCHRD) first took a wait-and-see approach.

“(With) almost 20 completed and 40 ongoing clinical trials around the world as reported in clinicaltrials.gov exploring the use of Ivermectin formulations against COVID-19, the Philippine Council for Health Research and Development (DOST-PCHRD) is of the position that there is no need to conduct another clinical trial in the Philippines,” the agency said in a statement in April 2021. (RA/TRC/Headline PH)

LEAVE A REPLY

Please enter your comment!
Please enter your name here